We Can Do Better Than HRD – Opportunities for New Biomarkers and Agents to Improve Outcomes

Presenters will examine the strength and limitations of current evidence supporting standard maintenance regimens alongside evolving data that may refine patient selection and improve outcomes in ovarian cancer. The discussion will address resistance, toxicity, and the future direction of personalized maintenance therapy. Faculty will provide expert insight into how these competing strategies may shape clinical practice. Explore emerging biomarkers and novel therapeutic agents shaping frontline maintenance strategies for ovarian cancer. Faculty will review evolving evidence on molecular and genomic markers that may better predict benefit and guide personalized maintenance therapy. The discussion will highlight investigational agents, mechanisms of resistance, and how these advances may complement or challenge current standards of care.